| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H27N3O |
| Molecular Weight | 313.4372 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1[C@H]2CC[C@@H]1C[C@@H](C2)NC(=O)N3CC(C)(C)C4=CC=CC=C34
InChI
InChIKey=ILXWRFDRNAKTDD-QDMKHBRRSA-N
InChI=1S/C19H27N3O/c1-19(2)12-22(17-7-5-4-6-16(17)19)18(23)20-13-10-14-8-9-15(11-13)21(14)3/h4-7,13-15H,8-12H2,1-3H3,(H,20,23)/t13-,14+,15-
| Molecular Formula | C19H27N3O |
| Molecular Weight | 313.4372 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Ricasetron (BRL 46470) is a selective serotonin 5-HT3 receptor antagonist. This compound was found to be a potent anxiolytic agent and have antiemetic (effective against vomiting and nausea) effects when tested in animal models. Moreover, this drug was reported to have less side effects than benzodiazepines (used for anxiety). Ricasetron was not further developed for medical use.
